Abstract
Overdose prevention health centers (OPHCs), also known as overdose prevention centers or safe injection centers, are an evidence-based strategy for people to use drugs in an environment monitored by health care professionals with access to drug use education, sterile supplies, and referral infrastructure to access higher levels of medical and behavioral health resources. Though still illegal under federal law throughout the United States, many legal or quasi-legal (including some in the United States) have operated since the 1980s (Beletsky, Baker et al. 2018). Using CDC overdose deaths and United States Census Bureau population data, we estimate over 14,000 deaths could be averted between 2020 and 2022 if 1 out of 20 injections had taken place at an OPHC. At this rate, over 100 HIV transmissions and 57,000 Hepatitis C Virus transmissions would have been averted as well. Almost 20 billion dollars in discounted lifetime costs to treat those infections could have been saved as well. This data supports OPHCs as a viable public health intervention to avert deaths and avoid infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by National Institute of General Medical Sciences 1T32GM152318-01.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Drug overdose deaths were accessed from the publicly available National Center for Health Statistics. Publicly available population and age data were downloaded from the United States Census Bureau.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Clarified that grant was from NIH in funding section. Uploaded new discussion section. No changes to results section.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
